Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Baxter
Chubb
Express Scripts
Deloitte
Medtronic
Dow
Covington
Queensland Health

Generated: May 23, 2018

DrugPatentWatch Database Preview

BESIVANCE Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

When do Besivance patents expire, and when can generic versions of Besivance launch?

Besivance is a drug marketed by Bausch And Lomb and is included in one NDA. There are six patents protecting this drug.

This drug has fifty-three patent family members in nineteen countries.

The generic ingredient in BESIVANCE is besifloxacin hydrochloride. There are four drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the besifloxacin hydrochloride profile page.
Summary for BESIVANCE
International Patents:53
US Patents:6
Applicants:1
NDAs:1
Suppliers / Packagers: 3
Bulk Api Vendors: 39
Clinical Trials: 12
Patent Applications: 13
DailyMed Link:BESIVANCE at DailyMed
Drug patent expirations by year for BESIVANCE
Pharmacology for BESIVANCE
Ingredient-typeQuinolones
Drug ClassQuinolone Antimicrobial
Synonyms for BESIVANCE
(+)-7-((3R)-3-Aminohexahydro-1H-azepin-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid hydrochloride
(R)-7-(3-aminoazepan-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid hydrochloride
(R)-7-(3-Aminohexahydro-1H-azepin-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid hydrochloride
165B619
3-Quinolinecarboxylic acid, 7-((3R)-3-aminohexahydro-1H-azepin-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-, monohydrochloride
405165-61-9
7-[(3R)-3-aminoazepan-1-yl]-8-chloro-1-cyclopropyl-6-fluoro-4-oxo-quinoline-3-carboxylic acid hydrochloride
7-[(3R)-3-Aminohexahydro-1H-azepin-1-yl]-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic Acid Hydrochloride
7506A6J57T
AB0095123
AC-23367
AK481596
AKOS025401618
AN-1100
AOB5079
API0007512
Besifloxacin (Hydrochloride)
Besifloxacin HCl
Besifloxacin HCl (Besivance)
Besifloxacin hydrochloride
Besifloxacin hydrochloride (USAN)
Besifloxacin hydrochloride [USAN]
Besivance (TN)
BG0675
BOL 303224a
BOL-303224-A
C19H22Cl2FN3O3
CCG-221259
CHEMBL1201761
CS-0713
D08872
DTXSID20193529
EX-A1339
FT-0663073
HY-17028
J-519840
MolPort-023-335-709
QC-1565
RL03558
s3055
SC-24925
SCHEMBL291598
SS-734
SS734
UNII-7506A6J57T
W-5589
X3492

US Patents and Regulatory Information for BESIVANCE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bausch And Lomb BESIVANCE besifloxacin hydrochloride SUSPENSION/DROPS;OPHTHALMIC 022308-001 May 28, 2009 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Bausch And Lomb BESIVANCE besifloxacin hydrochloride SUSPENSION/DROPS;OPHTHALMIC 022308-001 May 28, 2009 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Bausch And Lomb BESIVANCE besifloxacin hydrochloride SUSPENSION/DROPS;OPHTHALMIC 022308-001 May 28, 2009 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Bausch And Lomb BESIVANCE besifloxacin hydrochloride SUSPENSION/DROPS;OPHTHALMIC 022308-001 May 28, 2009 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Non-Orange Book US Patents for BESIVANCE

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,056,893 Topical treatment for prevention of ocular infections ➤ Try a Free Trial
6,239,113 Topical treatment or prevention of ocular infections ➤ Try a Free Trial
7,749,970 Topical treatment of prevention of ocular infections ➤ Try a Free Trial
7,732,415 Topical treatment or prevention of ocular infections ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Cantor Fitzgerald
Harvard Business School
Daiichi Sankyo
Citi
Moodys
Dow
UBS
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.